European Investor
23 Jun 2026, 14:27
AbbVie (NYSE: ABBV) gained 1.2% after receiving supportive analyst commentary, as Canaccord Genuity raised its price target to $273 from $265 and Cantor Fitzgerald reiterated its Overweight rating.
The positive analyst actions reflect continued confidence in AbbVie's growth outlook as the company strengthens its portfolio beyond Humira. Investors remain focused on the strong performance of newer immunology drugs Skyrizi and Rinvoq, which have become key drivers of revenue growth and market share gains.
Sentiment was also supported by AbbVie's recently announced acquisition of Apogee Therapeutics, a deal that expands the company's immunology pipeline and reinforces its long-term growth strategy. Analysts view the transaction as a move that could further strengthen AbbVie's leadership position in inflammatory diseases.
The stock's advance suggests investors remain optimistic about the company's ability to generate consistent earnings growth, supported by a diversified pharmaceutical portfolio, strong cash flow generation, and continued business development activity.
With multiple analysts maintaining bullish ratings and raising valuation targets, AbbVie continues to be viewed as one of the leading large-cap pharmaceutical companies positioned for sustainable growth in the years ahead.
The positive analyst actions reflect continued confidence in AbbVie's growth outlook as the company strengthens its portfolio beyond Humira. Investors remain focused on the strong performance of newer immunology drugs Skyrizi and Rinvoq, which have become key drivers of revenue growth and market share gains.
Sentiment was also supported by AbbVie's recently announced acquisition of Apogee Therapeutics, a deal that expands the company's immunology pipeline and reinforces its long-term growth strategy. Analysts view the transaction as a move that could further strengthen AbbVie's leadership position in inflammatory diseases.
The stock's advance suggests investors remain optimistic about the company's ability to generate consistent earnings growth, supported by a diversified pharmaceutical portfolio, strong cash flow generation, and continued business development activity.
With multiple analysts maintaining bullish ratings and raising valuation targets, AbbVie continues to be viewed as one of the leading large-cap pharmaceutical companies positioned for sustainable growth in the years ahead.